Akorn Announces the Sale of the Akorn-Strides Joint Venture Product Portfolio to Pfizer, Inc.
Business Wire › December 30, 2010
Linked as:
Extract
Akorn Announces the Sale of the Akorn-Strides Joint Venture Product Portfolio to Pfizer, Inc.
LAKE FOREST, Ill. -- Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today reported that its Akorn-Strides LLC joint venture has entered into a purchase agreement with Pfi...
See the full content of this document
Sponsored links
